Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29839308 | 1.00 | ALDH1A1 (0.38) | ALDH1A1OPRD1PROKR1MGLLKDM4E | |
| SCHEMBL22729413 | 0.93 | GRIN2B (0.35) | ALDH1A1OPRD1PROKR1KDM4EALOX15 | |
| SCHEMBL29839289 | 0.93 | GRIN2B (0.35) | ALDH1A1OPRD1PROKR1KDM4EALOX15 | |
| SCHEMBL22729868 | 0.90 | KDM4E (0.40) | ALDH1A1PROKR1MGLLKDM4EALOX15 | |
| SCHEMBL29839357 | 0.90 | MGLL (0.39) | ALDH1A1OPRD1MGLLKDM4EALOX15 | |
| SCHEMBL22729755 | 0.90 | MGLL (0.39) | ALDH1A1OPRD1MGLLKDM4EALOX15 | |
| SCHEMBL22729448 | 0.89 | MGLL (0.46) | ALDH1A1MGLLKDM4EALOX15MAPK1 | |
| SCHEMBL22729815 | 0.88 | ALDH1A1 (0.39) | ALDH1A1PROKR1MGLLKDM4EALOX15 | |
| SCHEMBL22729548 | 0.85 | MGLL (0.39) | ALDH1A1MGLLKDM4EALOX15MAPK1 | |
| SCHEMBL22729725 | 0.85 | APP (0.37) | ALDH1A1MGLLKDM4EALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | ALDH1A1 2626/4885OPRD1 4709/4885PROKR1 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.